AQST - Aquestive Therapeutics GAAP EPS of -$0.23 in-line revenue of $10.68M beats by $0.26M
2023-03-07 16:05:49 ET
- Aquestive Therapeutics press release ( NASDAQ: AQST ): Q4 GAAP EPS of -$0.23 in-line.
- Revenue of $10.68M beats by $0.26M .
- 2023 Outlook
- Aquestive is providing its full year 2023 financial outlook.
-
- Total revenue (in millions) - $37 to $41 vs $47.40M consensus.
- Non-GAAP adjusted EBITDA loss (in millions) - $31 to $36
For further details see:
Aquestive Therapeutics GAAP EPS of -$0.23 in-line, revenue of $10.68M beats by $0.26M